We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves Antibacterial Orbactiv, the Third ABSSSI Drug This Year Under New Incentive Pathway
FDA Approves Antibacterial Orbactiv, the Third ABSSSI Drug This Year Under New Incentive Pathway
The FDA has approved The Medicines Company’s intravenous skin disease treatment Orbactiv, the third such product cleared this year under a pathway that provides manufacturers incentives to develop new antibiotics for serious or life-threatening infections.